Singapore Clinical Trial: A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants with Advanced RCC who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)

Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants with Advanced RCC who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)'. The following are the other relevant details related to the trial:

Therapeutic Area: Oncology (including Haematology-Oncology)

Trial Centre(s): National Cancer Centre National University Hospital

Trial Status: NA

Principal Investigator(s): Dr Ravindran Kanesvaran Dr Alvin Wong Seng Cheong

Published by HT Digital Content Services with permission from Health Daily Digest....